Closure Medical (NASDAQ:CLSR)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more Closure Medical Charts. Click Here for more Closure Medical Charts.](/p.php?pid=staticchart&s=N%5ECLSR&p=8&t=15)
CLOSURE Medical Receives Medical Design Excellence Award
RALEIGH, N.C., April 13 /PRNewswire-FirstCall/ -- CLOSURE Medical Corporation ,
a global leader in biomaterial-based medical devices, announced today that it
has received a Medical Design Excellence Award from Canon Communications, the
publisher of Medical Device & Diagnostic Industry Journal, for its design of the
DERMABOND ProPen XL Applicator System.
(Photo: http://www.newscom.com/cgi-bin/prnh/20040413/LATU072)
The DERMABOND ProPen XL Applicator System provides physicians with greater
precision application and control of adhesive flow utilizing the High- Viscosity
DERMABOND Topical Skin Adhesive. The device is a disposable, sterile,
single-use medical delivery system, which is used by healthcare professionals as
a replacement for sutures and staples when closing incisions and lacerations.
All DERMABOND products are distributed by ETHICON, INC., a Johnson & Johnson
Company.
The Medical Design Excellence Awards competition is the only awards program that
exclusively recognizes contributions and advances in the design of medical
products. Products are evaluated on design and engineering features
incorporating innovative use of materials, user-related features that improve
healthcare delivery and change traditional medical attitudes or practices,
features that provide enhanced benefits to the patient and the ability of the
product development team to overcome design and engineering challenges so the
product meets its clinical objectives. A comprehensive review of the entries
was performed by an impartial, multidisciplinary panel of third-party judges
with expertise in biomedical engineering, human factors, industrial design,
medicine, diagnostics, and medical packaging.
"We are honored to be recognized by the Medical Design Excellence Awards for the
DERMABOND ProPen XL Applicator System," said William M. Cotter, Vice President
of Operations and Project Leader for ProPen XL. "We are dedicated to developing
and manufacturing products that fulfill the unmet needs of healthcare providers
and patients and feel that the ProPen XL product has greatly enhanced the ease
of use for physicians and practitioners."
The 2004 Medical Design Excellence Award recipients will be honored at a
ceremony during the Medical Design & Manufacturing East 2004 Conference and
Exposition, June 15-17, 2004 at New York City's Jacob K. Javits Convention
Center. Gold and Silver award recipients will be announced at this time.
About CLOSURE Medical Corporation
CLOSURE Medical Corporation is a global leader in the development and
manufacture of innovative biomaterial-based medical devices that fulfill the
needs of healthcare practitioners, patients and consumers.
For additional information on CLOSURE Medical visit its website at
http://www.closuremed.com/ or visit the "Clients" section of the Allen & Caron
website at http://www.allencaron.com/.
This release contains certain forward-looking statements which involve known and
unknown risks, delays, uncertainties or other factors not under the Company's
control which may cause actual results, performance or achievements of the
Company to be materially different from the results, performance, or other
expectations implied by these forward-looking statements. These factors
include, but are not limited to the early stage of commercialization of the
Company's products; the progress of its research and development programs for
future products; the need for regulatory approval and effects of governmental
regulation; technological uncertainties; the satisfactory conclusion of
negotiations with, and dependence on marketing partners, and dependence on
patents and trade secrets, as well as those detailed in the Company's Annual
Report on Form 10-K for the year ended December 31, 2003, filed with the
Securities and Exchange Commission. Although the Company believes that the
expectations in the forward-looking statements are reasonable, the Company
cannot guarantee such results. The Company undertakes no obligation to publicly
revise these forward-looking statements to reflect events or circumstances that
arise after the date hereof.
http://www.newscom.com/cgi-bin/prnh/20040413/LATU072
DATASOURCE: CLOSURE Medical Corporation
CONTACT: investors, Joe Allen, +1-212-691-8087, , or
media, Len Hall, +1-949-474-4300, , both of Allen & Caron
Inc for CLOSURE Medical Corporation; or Benny Ward, CFO of CLOSURE Medical
Corporation, +1-919-876-7800
Web site: http://www.allencaron.com/
Web site: http://www.closuremed.com/